TL;DR
This supplement contains abstracts accepted for the EACR 2025 Congress on innovative cancer science.
Contribution
Publication of selected abstracts from the EACR 2025 Congress in Molecular Oncology.
Findings
Abstracts were submitted to the EACR 2025 Congress and accepted by the organizing committee.
The accepted abstracts are published in a supplement of Molecular Oncology.
Abstract
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAdvanced Breast Cancer Therapies · Protein Degradation and Inhibitors · PARP inhibition in cancer therapy